Black Swan Analysis Epiomicâ„¢ Epidemiology Forecast Report on Congenital Adrenal Hyperplasia in 31 Major Markets
Congenital adrenal hyperplasia (CAH) is a group of genetic disorders associated with deficiencies of several adrenal enzymes which lead to abnormal production of glucocorticoids, mineralocorticoids and sex steroids. This, in turn, affects metabolism, sodium and water balance and the development of primary or secondary sex characteristics. CAH can occur in classic (severe) or non-classic (mild) forms depending on the amount of residue enzyme activity. This report covers only the classic form of the disorder.
This report provides the current prevalent population for CAH across 31 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Austria, Switzerland, Ireland, Czech Republic, Hungary, Romania, Croatia, Russia, Turkey, Egypt, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, CAH patients grouped by disease form have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of CAH include:
• Hypertension, hyperlipidaemia, diabetes and venous thromboembolism
• Osteoporosis/osteopaenia
• Growth impairment and short stature
• Infertility
• Respiratory and gastrointestinal infections
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Ability to quantify patient populations in global CAH market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of CAH and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Identification of CAH patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of CAH patients.
Epiomic Epidemiology Series: Congenital Adrenal Hyperplasia Forecast in 31 Major Markets 2018–2028
CONTENTS
• LIST OF TABLES AND FIGURES
• INTRODUCTION
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• TOP-LINE PREVALENCE FOR CONGENITAL ADRENAL HYPERPLASIA
• FEATURES OF CONGENITAL ADRENAL HYPERPLASIA PATIENTS
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
• REFERENCES
• APPENDIX
LIST OF TABLES AND FIGURES
• Table 1. Typical clinical characteristics of CAH patients by type of mutation
• Table 2. Prevalence of CAH, total (000s)
• Table 3. Prevalence of CAH, males (000s)
• Table 4. Prevalence of CAH, females (000s)
• Table 5. Patients with CAH by form, total (000s)
• Table 6. Abbreviations and acronyms used in the report
• Table 7. USA prevalence of CAH by 5-yr age cohort, males (000s)
• Table 8. USA prevalence of CAH by 5-yr age cohort, females (000s)
• Table 9. Canada prevalence of CAH by 5-yr age cohort, males (000s)
• Table 10. Canada prevalence of CAH by 5-yr age cohort, females (000s)
• Table 11. France prevalence of CAH by 5-yr age cohort, males (000s)
• Table 12. France prevalence of CAH by 5-yr age cohort, females (000s)
• Table 13. Germany prevalence of CAH by 5-yr age cohort, males (000s)
• Table 14. Germany prevalence of CAH by 5-yr age cohort, females (000s)
• Table 15. Italy prevalence of CAH by 5-yr age cohort, males (000s)
• Table 16. Italy prevalence of CAH by 5-yr age cohort, females (000s)
• Table 17. Spain prevalence of CAH by 5-yr age cohort, males (000s)
• Table 18. Spain prevalence of CAH by 5-yr age cohort, females (000s)
• Table 19. UK prevalence of CAH by 5-yr age cohort, males (000s)
• Table 20. UK prevalence of CAH by 5-yr age cohort, females (000s)
• Table 21. Poland prevalence of CAH by 5-yr age cohort, males (000s)
• Table 22. Poland prevalence of CAH by 5-yr age cohort, females (000s)
• Table 23. Netherlands prevalence of CAH by 5-yr age cohort, males (000s)
• Table 24. Netherlands prevalence of CAH by 5-yr age cohort, females (000s)
• Table 25. Belgium prevalence of CAH by 5-yr age cohort, males (000s)
• Table 26. Belgium prevalence of CAH by 5-yr age cohort, females (000s)
• Table 27. Norway prevalence of CAH by 5-yr age cohort, males (000s)
• Table 28. Norway prevalence of CAH by 5-yr age cohort, females (000s)
• Table 29. Sweden prevalence of CAH by 5-yr age cohort, males (000s)
• Table 30. Sweden prevalence of CAH by 5-yr age cohort, females (000s)
• Table 31. Denmark prevalence of CAH by 5-yr age cohort, males (000s)
• Table 32. Denmark prevalence of CAH by 5-yr age cohort, females (000s)
• Table 33. Austria prevalence of CAH by 5-yr age cohort, males (000s)
• Table 34. Austria prevalence of CAH by 5-yr age cohort, females (000s)
• Table 35. Switzerland prevalence of CAH by 5-yr age cohort, males (000s)
• Table 36. Switzerland prevalence of CAH by 5-yr age cohort, females (000s)
• Table 37. Ireland prevalence of CAH by 5-yr age cohort, males (000s)
• Table 38. Ireland prevalence of CAH by 5-yr age cohort, females (000s)
• Table 39. Czech Republic prevalence of CAH by 5-yr age cohort, males (000s)
• Table 40. Czech Republic prevalence of CAH by 5-yr age cohort, females (000s)
• Table 41. Hungary prevalence of CAH by 5-yr age cohort, males (000s)
• Table 42. Hungary prevalence of CAH by 5-yr age cohort, females (000s)
• Table 43. Romania prevalence of CAH by 5-yr age cohort, males (000s)
• Table 44. Romania prevalence of CAH by 5-yr age cohort, females (000s)
• Table 45. Croatia prevalence of CAH by 5-yr age cohort, males (000s)
• Table 46. Croatia prevalence of CAH by 5-yr age cohort, females (000s)
• Table 47. Russia prevalence of CAH by 5-yr age cohort, males (000s)
• Table 48. Russia prevalence of CAH by 5-yr age cohort, females (000s)
• Table 49. Turkey prevalence of CAH by 5-yr age cohort, males (000s)
• Table 50. Turkey prevalence of CAH by 5-yr age cohort, females (000s)
• Table 51. Egypt prevalence of CAH by 5-yr age cohort, males (000s)
• Table 52. Egypt prevalence of CAH by 5-yr age cohort, females (000s)
• Table 53. Japan prevalence of CAH by 5-yr age cohort, males (000s)
• Table 54. Japan prevalence of CAH by 5-yr age cohort, females (000s)
• Table 55. China prevalence of CAH by 5-yr age cohort, males (000s)
• Table 56. China prevalence of CAH by 5-yr age cohort, females (000s)
• Table 57. South Korea prevalence of CAH by 5-yr age cohort, males (000s)
• Table 58. South Korea prevalence of CAH by 5-yr age cohort, females (000s)
• Table 59. India prevalence of CAH by 5-yr age cohort, males (000s)
• Table 60. India prevalence of CAH by 5-yr age cohort, females (000s)
• Table 61. Australia prevalence of CAH by 5-yr age cohort, males (000s)
• Table 62. Australia prevalence of CAH by 5-yr age cohort, females (000s)
• Table 63. Brazil prevalence of CAH by 5-yr age cohort, males (000s)
• Table 64. Brazil prevalence of CAH by 5-yr age cohort, females (000s)
• Table 65. Mexico prevalence of CAH by 5-yr age cohort, males (000s)
• Table 66. Mexico prevalence of CAH by 5-yr age cohort, females (000s)
• Table 67. Argentina prevalence of CAH by 5-yr age cohort, males (000s)
• Table 68. Argentina prevalence of CAH by 5-yr age cohort, females (000s)
